Oliver Riedel1, C Ohlmeier2,3, D Enders2, A Elsässer4, D Vizcaya5, A Michel5, S Eberhard6, N Schlothauer7, J Berg8, E Garbe2. 1. Leibniz Institute for Prevention Research and Epidemiology - BIPS, Achterstrasse 30, 28359, Bremen, Germany. riedel@leibniz-bips.de. 2. Leibniz Institute for Prevention Research and Epidemiology - BIPS, Achterstrasse 30, 28359, Bremen, Germany. 3. IGES Institut GmbH, Berlin, Germany. 4. Department of Cardiology, Klinikum Oldenburg, AöR, Oldenburg, Germany. 5. Epidemiology, Bayer AG, Berlin, Germany. 6. AOK Niedersachsen, Hanover, Germany. 7. Hausarztpraxis Dr. Stephan Spiekermann&Partner im Gesundheitszentrum, Delmenhorst, Germany. 8. AOK Bremen/Bremerhaven, Bremerhaven, Germany.
Abstract
BACKGROUND: Heart failure (HF) with reduced ejection fraction (HFrEF) has a worse prognosis than HF with preserved EF (HFpEF). The study aimed to evaluate whether different comorbidity profiles of HFrEF- and HFpEF-patients or HF-specific mechanisms contribute to a greater extent to this difference. METHODS: We linked data from two health insurances to data from a cardiology clinic hospital information system. Patients with a hospitalization with HF in 2005-2011, categorized as HFrEF (EF < 45%) or HFpEF (EF ≥ 45%), were propensity score (PS) matched to controls without HF on comorbidites and medication to assure similar comorbidity profiles of patients and their respective controls. The balance of the covariates in patients and controls was compared via the standardized difference (SDiff). Age-standardized 1-year mortality rates (MR) with 95% confidence intervals (CI) were calculated. RESULTS: 777 HFrEF-patients (1135 HFpEF-patients) were PS-matched to 3446 (4832) controls. Balance between patients and controls was largely achieved with a SDiff < 0.1 on most variables considered. The age-standardized 1-year MRs per 1000 persons in HFrEF-patients and controls were 267.8 (95% CI 175.9-359.8) and 86.1 (95% CI 70.0-102.3). MRs in HFpEF-patients and controls were 166.2 (95% CI 101.5-230.9) and 61.5 (95% CI 52.9-70.1). Thus, differences in MRs between patients and their controls were higher for HFrEF (181.7) than for HFpEF (104.7). CONCLUSIONS: Given the similar comorbidity profiles between HF-patients and controls, the higher difference in mortality rates between HFrEF-patients and controls points more to HF-specific mechanisms for these patients, whereas for HFpEF-patients a higher contribution of comorbidity is suggested by our results.
BACKGROUND:Heart failure (HF) with reduced ejection fraction (HFrEF) has a worse prognosis than HF with preserved EF (HFpEF). The study aimed to evaluate whether different comorbidity profiles of HFrEF- and HFpEF-patients or HF-specific mechanisms contribute to a greater extent to this difference. METHODS: We linked data from two health insurances to data from a cardiology clinic hospital information system. Patients with a hospitalization with HF in 2005-2011, categorized as HFrEF (EF < 45%) or HFpEF (EF ≥ 45%), were propensity score (PS) matched to controls without HF on comorbidites and medication to assure similar comorbidity profiles of patients and their respective controls. The balance of the covariates in patients and controls was compared via the standardized difference (SDiff). Age-standardized 1-year mortality rates (MR) with 95% confidence intervals (CI) were calculated. RESULTS: 777 HFrEF-patients (1135 HFpEF-patients) were PS-matched to 3446 (4832) controls. Balance between patients and controls was largely achieved with a SDiff < 0.1 on most variables considered. The age-standardized 1-year MRs per 1000 persons in HFrEF-patients and controls were 267.8 (95% CI 175.9-359.8) and 86.1 (95% CI 70.0-102.3). MRs in HFpEF-patients and controls were 166.2 (95% CI 101.5-230.9) and 61.5 (95% CI 52.9-70.1). Thus, differences in MRs between patients and their controls were higher for HFrEF (181.7) than for HFpEF (104.7). CONCLUSIONS: Given the similar comorbidity profiles between HF-patients and controls, the higher difference in mortality rates between HFrEF-patients and controls points more to HF-specific mechanisms for these patients, whereas for HFpEF-patients a higher contribution of comorbidity is suggested by our results.
Authors: Eileen M Hsich; Maria V Grau-Sepulveda; Adrian F Hernandez; Eric D Peterson; Lee H Schwamm; Deepak L Bhatt; Gregg C Fonarow Journal: Am Heart J Date: 2012-03 Impact factor: 4.749
Authors: Frank P Brouwers; Rudolf A de Boer; Pim van der Harst; Adriaan A Voors; Ron T Gansevoort; Stephan J Bakker; Hans L Hillege; Dirk J van Veldhuisen; Wiek H van Gilst Journal: Eur Heart J Date: 2013-03-06 Impact factor: 29.983
Authors: Michael R MacDonald; Mark C Petrie; Fumi Varyani; Jan Ostergren; Eric L Michelson; James B Young; Scott D Solomon; Christopher B Granger; Karl Swedberg; Salim Yusuf; Marc A Pfeffer; John J V McMurray Journal: Eur Heart J Date: 2008-04-14 Impact factor: 29.983
Authors: Gregg C Fonarow; Wendy Gattis Stough; William T Abraham; Nancy M Albert; Mihai Gheorghiade; Barry H Greenberg; Christopher M O'Connor; Jie Lena Sun; Clyde W Yancy; James B Young Journal: J Am Coll Cardiol Date: 2007-08-06 Impact factor: 24.094
Authors: Barry M Massie; Peter E Carson; John J McMurray; Michel Komajda; Robert McKelvie; Michael R Zile; Susan Anderson; Mark Donovan; Erik Iverson; Christoph Staiger; Agata Ptaszynska Journal: N Engl J Med Date: 2008-11-11 Impact factor: 91.245
Authors: Daniel Contaifer; Leo F Buckley; George Wohlford; Naren G Kumar; Joshua M Morriss; Asanga D Ranasinghe; Salvatore Carbone; Justin M Canada; Cory Trankle; Antonio Abbate; Benjamin W Van Tassell; Dayanjan S Wijesinghe Journal: PLoS One Date: 2019-06-20 Impact factor: 3.240
Authors: Carmine Bruno; Andrea Silvestrini; Rodolfo Calarco; Angela M R Favuzzi; Edoardo Vergani; Maria Anna Nicolazzi; Claudia d'Abate; Elisabetta Meucci; Alvaro Mordente; Raffaele Landolfi; Antonio Mancini Journal: Front Endocrinol (Lausanne) Date: 2020-05-12 Impact factor: 5.555
Authors: Jan Wintrich; Ingrid Kindermann; Christian Ukena; Simina Selejan; Christian Werner; Christoph Maack; Ulrich Laufs; Carsten Tschöpe; Stefan D Anker; Carolyn S P Lam; Adriaan A Voors; Michael Böhm Journal: Clin Res Cardiol Date: 2020-03-31 Impact factor: 5.460
Authors: Ahmad Shoaib; M Farag; J Nolan; A Rigby; A Patwala; M Rashid; C S Kwok; R Perveen; A L Clark; M Komajda; J G F Cleland Journal: Clin Res Cardiol Date: 2018-10-25 Impact factor: 5.460
Authors: Christoph Fisser; Kristina Götz; Andrea Hetzenecker; Kurt Debl; Florian Zeman; Okka W Hamer; Florian Poschenrieder; Claudia Fellner; Stefan Stadler; Lars S Maier; Michael Pfeifer; Stefan Buchner; Michael Arzt Journal: Clin Res Cardiol Date: 2020-06-09 Impact factor: 5.460